Literature DB >> 23820464

Cannabis use is associated with increased CCL11 plasma levels in young healthy volunteers.

Emilio Fernandez-Egea1, Linda Scoriels, Swathi Theegala, Maria Giro, Susan E Ozanne, Keith Burling, Peter B Jones.   

Abstract

Cannabis is a widely used recreational drug. Its effect on human health and psychosis remains controversial. In this study, we aimed to explore the possibility that cannabis use influenced CCL11 plasma levels. Increased CCL11 chemokine has been reported in schizophrenia and cannabis is a known trigger of schizophrenia. Additionally, plasma levels of the chemokine CCL11 have recently been shown to increase with age and with cognitive deficits and hippocampal neurogenesis. For this study, a total of 87 healthy volunteers (68% men, age range 18-35 years) completed the Cannabis Experience Questionnaire that included information on sociodemographic and morphometric data and provided a blood sample for CCL11 measurement. 'Current users' of cannabis (n=18) had significantly higher CCL11 plasma levels compared to 'past users' (n=33) and 'never users' (n=36) [F(3,84)=3.649; p=0.030]. The latter two groups had similar CCL11 levels. Higher CCL11 plasma levels could not be attributed to gender, age, body mass index, physical activity or use of other legal/illegal drugs. These results suggest that cannabis use increases CCL11 plasma levels and the effects are reversible when cannabis use ceases.
© 2013.

Entities:  

Keywords:  Aging; BMI; Body mass index; CCL11; CEQ; Cannabis; Cannabis Experience Questionnaire; Chemokine; PAI; Physical Activity Index; Psychosis; SD; Schizophrenia; Standard deviation

Mesh:

Substances:

Year:  2013        PMID: 23820464     DOI: 10.1016/j.pnpbp.2013.06.011

Source DB:  PubMed          Journal:  Prog Neuropsychopharmacol Biol Psychiatry        ISSN: 0278-5846            Impact factor:   5.067


  6 in total

1.  Rapid transport of CCL11 across the blood-brain barrier: regional variation and importance of blood cells.

Authors:  Michelle A Erickson; Yoichi Morofuji; Joshua B Owen; William A Banks
Journal:  J Pharmacol Exp Ther       Date:  2014-04-04       Impact factor: 4.030

2.  Multi-method genome- and epigenome-wide studies of inflammatory protein levels in healthy older adults.

Authors:  Robert F Hillary; Daniel Trejo-Banos; Athanasios Kousathanas; Daniel L McCartney; Sarah E Harris; Anna J Stevenson; Marion Patxot; Sven Erik Ojavee; Qian Zhang; David C Liewald; Craig W Ritchie; Kathryn L Evans; Elliot M Tucker-Drob; Naomi R Wray; Allan F McRae; Peter M Visscher; Ian J Deary; Matthew R Robinson; Riccardo E Marioni
Journal:  Genome Med       Date:  2020-07-08       Impact factor: 11.117

3.  Inflammatory mediators and dual depression: Potential biomarkers in plasma of primary and substance-induced major depression in cocaine and alcohol use disorders.

Authors:  Nuria García-Marchena; Marta Barrera; Joan Ignasi Mestre-Pintó; Pedro Araos; Antonia Serrano; Clara Pérez-Mañá; Esther Papaseit; Francina Fonseca; Juan Jesús Ruiz; Fernando Rodríguez de Fonseca; Magí Farré; Francisco Javier Pavón; Marta Torrens
Journal:  PLoS One       Date:  2019-03-14       Impact factor: 3.240

4.  Immune System Abnormalities in Schizophrenia: An Integrative View and Translational Perspectives.

Authors:  Evgeny A Ermakov; Mark M Melamud; Valentina N Buneva; Svetlana A Ivanova
Journal:  Front Psychiatry       Date:  2022-04-25       Impact factor: 5.435

5.  Preparedness for healthy ageing and polysubstance use in long-term cannabis users: a population-representative longitudinal study.

Authors:  Madeline H Meier; Avshalom Caspi; Antony Ambler; Ahmad R Hariri; HonaLee Harrington; Sean Hogan; Renate Houts; Annchen R Knodt; Sandhya Ramrakha; Leah S Richmond-Rakerd; Richie Poulton; Terrie E Moffitt
Journal:  Lancet Healthy Longev       Date:  2022-10

Review 6.  Inflammatory Biomarkers in Addictive Disorders.

Authors:  Alvaro Morcuende; Francisco Navarrete; Elena Nieto; Jorge Manzanares; Teresa Femenía
Journal:  Biomolecules       Date:  2021-12-03
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.